Title |
Intervention | NCT ID | Sponsor | Status |
|---|---|---|---|---|
| Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and... | Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Ondansetron Hydrochloride, Palonosetron Hydrochloride, Placebo | NCT03578081 | Alliance for Clinical Trials in Oncology | Active, not recruiting |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer... | Megestrol Acetate, Olanzapine, Questionnaire Administration | NCT04939090 | Alliance for Clinical Trials in Oncology | Not yet recruiting |
| Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by... | Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration | NCT03757949 | Southwest Oncology Group | Recruiting |
| New Assessment System in Measuring Symptom Distress in Cancer Patients | Interview, Quality-of-Life Assessment, Questionnaire Administration | NCT00505245 | M.D. Anderson Cancer Center | Recruiting |
| Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or... | Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment | NCT03367572 | University of Rochester NCORP Research Base | Recruiting |
| Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure | NCT02636582 | National Cancer Institute (NCI) | Active, not recruiting |
| NCI COVID-19 in Cancer Patients, NCCAPS Study | Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration | NCT04387656 | National Cancer Institute (NCI) | Recruiting |
| National Cancer Institute "Cancer Moonshot Biobank" | Biospecimen Collection, Medical Chart Review | NCT04314401 | National Cancer Institute (NCI) | Recruiting |
| Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Laboratory Biomarker Analysis, Naloxegol, Placebo, Quality-of-Life Assessment | NCT03087708 | Alliance for Clinical Trials in Oncology | Active, not recruiting |
| Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | NCT03998202 | Wake Forest University Health Sciences | Recruiting |
Why I Joined a Clinical Trial
I enrolled in the trial, in part, because I wanted to be able to tell my future patients that, when given the opportunity to participate in a clinical trial, I did so. If I was fortunate enough to survive my malignancy, I felt that my personal involvement in a clinical trial strengthened my endorsement of clinical trial participation for my future patients. Patients should know that the focus of cancer-related investigation extends beyond traditional cancer-related endpoints and into the control of cancer- and treatment-related symptoms.